Vaxcyte (PCVX) Q3 2026 earnings review
Vaxcyte's pneumonia vaccine clears trial, while spending drains cash
Vaxcyte, a clinical-stage developer of bacterial vaccines, cleared its main late-stage adult pneumonia trial while spending heavily on development. Research costs rose 29% from a year ago to $270 million, pushing the third-quarter net loss to $297 million. Following the trial win, chief executive Grant Pickering set a first-half 2028 target to file for US approval, and the company raised $1.1 billion in October to lift pro forma cash to $3.4 billion.
| Pro forma cash and investments | ~$3.4B includes $1.1B net from October offerings |
|---|---|
| Research and development expense | $270M +29% from a year ago |
| Net loss | $297M $213M a year ago |
| Adult vaccine filing plan | 1H 2028 first issued after OPUS-1 win |
⚖️ Verdict: 🟢 Bullish
The story got better because the OPUS-1 trial proved VAX-31 can cover 31 bacterial strains safely and meet all primary goals, while the October financing removes funding risk through the planned filing. One caution: when compared directly against Merck's Capvaxive alone, VAX-31 missed the stricter immune-response threshold on two of 19 shared strains, and the company noted regulators will focus closely on the Merck comparison.
The question now is whether regulators and doctors weigh VAX-31's ten extra strains more heavily than its softer response on two strains shared with Merck's shot. If breadth matters most, VAX-31 becomes the preferred adult shot; if peak response on Merck's strains dominates, rivals keep a share of the market. The OPUS-3 readout in previously vaccinated adults during the first half of 2027 will test how the vaccine performs across a wider group.
🐂 Bull Case
Adult Vaccine Trial Cleared Its Main Goals
Vaxcyte is developing VAX-31, a shot designed to prevent bacterial pneumonia and blood infections across 31 strains, more than any rival vaccine on the market. In October, the biotech group reported results from OPUS-1, its main late-stage trial in 4,047 adults. “VAX-31 met all prespecified primary endpoints in this pivotal Phase 3 trial, which inaugurated a more stringent noninferiority standard, and we believe the results further support its potential best-in-class profile.” Chief executive Grant Pickering said.
- Shared strains meeting main goal: 28 out of 28 when tested against Pfizer's Prevnar 20 or Merck's Capvaxive
- Strains shared with Pfizer's shot: 20 out of 20 met the stricter 0.667 immune-response threshold
- New strains unique to VAX-31: 4 out of 4 met superiority goals
- Younger adults aged 18 to 49: 32 out of 32 strain comparisons matched responses in older adults
The trial succeeded because VAX-31 triggered strong immune responses across all 28 shared strains without causing vaccine-related serious side effects. That result matters because OPUS-1 forms the foundation of the company's planned application for US regulatory approval in the first half of 2028.
What to watch: results from the OPUS-2 and OPUS-3 trials in the first half of 2027. Positive readouts in previously vaccinated adults would support a broad recommendation across the entire older adult population.
October Offerings Added $1.1 Billion in Cash
Developing vaccines for thousands of patients and building commercial factories requires billions of dollars before a single dose is sold. Following the October trial readout, finance chief Andrew Guggenhime raised $1.1 billion in net proceeds “to further strengthen our balance sheet and extend our cash runway”. The financing split $1.15 billion in gross proceeds evenly between common stock and pre-funded warrants, and convertible debt paying 1.5% annual interest until October 2032.
Adding this cash lifts Vaxcyte's pro forma holdings to about $3.4 billion as of September 30, up 34.2% from June by our math. Because the convertible notes carry a 1.5% coupon, the drugmaker secured half the funding with minimal interest cost while limiting immediate share dilution. What to watch: quarterly cash balances in 2027, as keeping holdings above $2.5 billion would confirm the money can last through the planned 2028 regulatory filing.
🐻 Bear Case
Two Strains Missed Strict Target Against Merck
Pickering said the OPUS-1 results support a potential best-in-class profile for VAX-31. However, the trial tested VAX-31 against two marketed vaccines separately: Pfizer's 20-strain Prevnar 20 and Merck's 21-strain Capvaxive. To win the primary analysis on the 11 strains present in all three shots, Vaxcyte's rule only required beating one rival per strain.
When measured directly against Merck's shot alone, VAX-31 met the stricter 0.667 immune-response standard on 17 of 19 shared strains, or 89.5% by our math. It missed that stricter bar on serotypes 3 and 12F, clearing only an older 0.5 threshold. In prior quarters, Pickering dismissed serotype 3 as an outlier that no vaccine addresses well.
Yet the drugmaker noted in this release that strains unique to Merck's vaccine cause a larger share of US adult disease than those unique to Pfizer's. Because of that disease pattern, Vaxcyte expects the head-to-head comparison against Merck's shot to be “a particular focus of FDA review”. Missing the stricter target on two strains gives Merck a counter-argument when doctors choose between the two shots.
What to watch: full immune-response ratios from OPUS-3 in the first half of 2027. Another miss on serotype 3 or 12F would confirm that VAX-31 trades off peak response on certain strains for wider coverage.
Quarterly Cash Drain Reached $243 Million
Running three late-stage adult trials, a mid-stage infant study and commercial manufacturing scale-up is driving Vaxcyte's costs higher. In the third quarter, research and development spending rose 28.8% from a year ago to $270.3 million, pushing the quarterly net loss up 39.6% to $297.1 million.
By our math, Vaxcyte's cash and investment holdings dropped by $243.3 million during the three months ended September 30. That quarterly drain equals nearly $1 billion a year, which explains why management raised money in October despite holding $2.26 billion. What to watch: fourth-quarter research and development spending, because a drop below $250 million would show trial costs are peaking now that OPUS-1 is finished.
Strep Vaccine Trial Added a Third Shot
Beyond pneumonia, Vaxcyte is testing VAX-A1, an early-stage vaccine meant to prevent Group A Strep infections, in an 80-adult Australian trial launched in June. After an independent safety board reviewed the first stage, the company changed the trial design to find “the dose that best balances immune response and tolerability”.
Vaxcyte added a third vaccination to the low and mid-dose groups, which previously used two shots, and pushed the high-dose group into a separate third stage requiring another safety review. Adding doses and gating the highest strength suggests two shots at lower levels were not strong enough, or higher doses raised tolerability questions. What to watch: initial VAX-A1 data in the second half of 2027, where weak two-dose immune responses would confirm the shot needs a harder three-dose schedule.
👓 Other Themes
Vaccine Industry Veterans Joined Leadership
As Vaxcyte prepares for regulatory filings and commercial launches, it hired two industry executives in September. Dr. Luis Jodar joined as chief medical officer after 17 years at Pfizer, where he led vaccines and infectious diseases, and David McAvoy joined from Teva Pharmaceutical as chief legal officer. These hires follow the October 2025 appointment of a chief commercial officer and build out the team needed for FDA review.
💲 Other KPIs
Share count rose 9.3% from a year ago and 3.1% from last quarter, reflecting the 12.65 million shares sold in February 2026. This figure does not yet include the $575 million stock and warrant offering completed in October, which will push the share count higher in the fourth quarter.
Overhead costs increased 17.0% from a year ago and 8.7% from the second quarter, driven by hiring and consulting fees as the biotech firm builds commercial infrastructure. Stock-based compensation made up $17.0 million of this total, nearly unchanged from $16.9 million a year earlier.
Interest earned on cash reserves fell 20.7% from $29.3 million a year ago and 10.0% from the second quarter. The decline tracked the company's lower cash balance prior to the October financing, which reduced the cushion offsetting operating losses.
🔮 Guidance
New. Following the October readout of OPUS-1, Vaxcyte set its target for submitting a Biologics License Application to US regulators for the first half of 2028. The filing depends on completing the remaining adult trials and a manufacturing consistency study.
Unchanged. The company still expects safety and immune-response data from both remaining adult Phase 3 studies in the first half of next year. Both trials have finished enrolling their 1,390 and 752 participants.
Unchanged. Management kept its timeline to report data from both the initial three-dose series and the booster shot, either one after another or together, by mid-2027.
Unchanged. Despite adding a third vaccination for lower doses and moving the high dose into a new third stage, the company held its target for initial adult results in the second half of 2027.
❓ Key Questions
Why did VAX-A1 need a third dose and stage?
The safety board review led Vaxcyte to add a third shot for low and mid doses and delay the high dose into Stage 3. Management did not say whether weak immune responses or side effects drove this change.
How far did serotypes 3 and 12F trail Capvaxive?
VAX-31 missed the stricter 0.667 threshold against Merck's vaccine on serotypes 3 and 12F, clearing only the 0.5 bar. Exact immune-response ratios will show how closely the FDA might scrutinize those two strains.
When does the manufacturing consistency trial start and finish?
Submitting the adult license application in the first half of 2028 requires a final Phase 3 manufacturing consistency study. Vaxcyte has not yet disclosed the enrollment size or start date for this trial.
How many shares and warrants were issued in October?
The October financing raised $575 million from stock and pre-funded warrants, plus $575 million in convertible notes. The release did not specify the exact number of shares, warrant terms, or the conversion price on the debt.